title: Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis.
abstract: OBJECTIVE
  To analyse the impact of infliximab treatment on the number of hospital inpatient days and days of sick leave in patients with active ankylosing spondylitis (AS).
  
  
  METHODS
  The data of a 2 year open extension study of a 12 week, double blind, randomised, placebo controlled trial, in which all patients with AS were treated with 5 mg/kg infliximab, were used to investigate the effect of anti-TNF treatment on admissions to hospital and days of sick leave. All patients were interviewed at baseline and at regular intervals during the study to collect this information by questionnaires. Patients who completed 2 years of treatment (n = 49) and those who did not (n = 20) were analysed separately. Sick leave analysis was restricted to currently employed patients (n = 38).
  
  
  RESULTS
  During the 12 months before the screening visit, 20/49 (41%) completers had been admitted to hospital. After 1 and 2 years of treatment this percentage was reduced to 5/49 (10%; p<0.01), corresponding to a significant decrease in the mean number of inpatient days: from 11.1 to 0.6 after 1 year (p<0.01) and 2.9 after 2 years (p<0.01), respectively. No changes were seen in the dropout group.
  
  
  CONCLUSIONS
  The use of infliximab in patients with active AS reduces some important costs of AS, but additional studies with detailed cost calculations are needed.
authors.affiliation: Deutsches Rheuma-Forschungszentrum, Berlin, Germany. listing@drfz.de.
authors.forename: J
authors.initials: J
authors.lastname: Listing
authors.forename: J
authors.initials: J
authors.lastname: Brandt
authors.forename: M
authors.initials: M
authors.lastname: Rudwaleit
authors.forename: A
authors.initials: A
authors.lastname: Zink
authors.forename: J
authors.initials: J
authors.lastname: Sieper
authors.forename: J
authors.initials: J
authors.lastname: Braun
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D017281:Cost of Illness; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018582:Sick Leave / Q000706:statistics & numerical data*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000534:rehabilitation; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab